Around 36% of employers said they provide coverage of GLP-1s for both diabetes and weight loss, the same as 2025 and up from 34% in 2024, the survey said.
A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions.
As new GLP-1 drugs enter the U.S. market and landmark Medicare ... [3651 chars]